Free Trial

Robert W. Baird's Rating of Larimar Therapeutics on 6/30/2026

On June 30, 2026, Robert W. Baird updated its outlook on Larimar Therapeutics (NASDAQ:LRMR) with the action "Lower Price Target", setting a price target of $5.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Robert W. Baird

DateCompanyAction
11/11/2026
Black Rock Coffee Bar, Inc. stock logo
BRCB
Black Rock Coffee Bar
Boost Price Target
11/11/2026
RideNow Group, Inc. stock logo
RDNW
RideNow Group
Lower Price Target
11/11/2026
ALH
Alliance Laundry
Lower Price Target
11/11/2026
Core & Main, Inc. stock logo
CNM
Core & Main
Lower Price Target
11/11/2026
Lineage, Inc. stock logo
LINE
Lineage
Lower Price Target
11/11/2026
BrightView Holdings, Inc. stock logo
BV
BrightView
Lower Price Target
More Ratings From Robert W. Baird